These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 12591045

  • 1. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
    Metz DC, Soffer E, Forsmark CE, Cryer B, Chey W, Bochenek W, Pisegna JR.
    Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045
    [Abstract] [Full Text] [Related]

  • 2. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC, Forsmark C, Lew EA, Starr JA, Soffer EF, Bochenek W, Pisegna JR.
    Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
    [Abstract] [Full Text] [Related]

  • 3. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.
    Metz DC, Comer GM, Soffer E, Forsmark CE, Cryer B, Chey W, Pisegna JR.
    Aliment Pharmacol Ther; 2006 Feb 01; 23(3):437-44. PubMed ID: 16423003
    [Abstract] [Full Text] [Related]

  • 4. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
    Ramdani A, Mignon M, Samoyeau R.
    Gastroenterol Clin Biol; 2002 Apr 01; 26(4):355-9. PubMed ID: 12070410
    [Abstract] [Full Text] [Related]

  • 5. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, Walsh JH, Beg M, Bochenek W, Metz DC.
    Gastroenterology; 2000 Apr 01; 118(4):696-704. PubMed ID: 10734021
    [Abstract] [Full Text] [Related]

  • 6. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M, Pospai D, Forestier S, Vatier J, Vallot T.
    Clin Ther; 1993 Apr 01; 15 Suppl B():22-31. PubMed ID: 8205592
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
    Pisegna JR, Martin P, McKeand W, Ohning G, Walsh JH, Paul J.
    Am J Gastroenterol; 1999 Oct 01; 94(10):2874-80. PubMed ID: 10520836
    [Abstract] [Full Text] [Related]

  • 8. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
    Morocutti A, Merrouche M, Bjaaland T, Humphries T, Mignon M.
    Aliment Pharmacol Ther; 2006 Nov 15; 24(10):1439-44. PubMed ID: 17081164
    [Abstract] [Full Text] [Related]

  • 9. Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome.
    Désir B, Poitras P.
    Can J Gastroenterol; 2001 Dec 15; 15(12):795-8. PubMed ID: 11773945
    [Abstract] [Full Text] [Related]

  • 10. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
    Metz DC, Pratha V, Martin P, Paul J, Maton PN, Lew E, Pisegna JR.
    Am J Gastroenterol; 2000 Mar 15; 95(3):626-33. PubMed ID: 10710049
    [Abstract] [Full Text] [Related]

  • 11. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Cheer SM, Prakash A, Faulds D, Lamb HM.
    Drugs; 2003 Mar 15; 63(1):101-33. PubMed ID: 12487624
    [Abstract] [Full Text] [Related]

  • 12. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects.
    Koop H, Kuly S, Flüg M, Eissele R, Mönnikes H, Rose K, Lühmann R, Schneider A, Fischer R, Arnold R.
    Eur J Gastroenterol Hepatol; 1996 Sep 15; 8(9):915-8. PubMed ID: 8889461
    [Abstract] [Full Text] [Related]

  • 13. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.
    Hirschowitz BI, Simmons J, Mohnen J.
    Aliment Pharmacol Ther; 2001 Nov 15; 15(11):1795-806. PubMed ID: 11683694
    [Abstract] [Full Text] [Related]

  • 14. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
    Mignon M, Hochlaf S, Forestier S, Ruszniewski P, Vatier J, Joubert-Collin M.
    Gastroenterol Clin Biol; 1994 Nov 15; 18(1):13-6. PubMed ID: 8187984
    [Abstract] [Full Text] [Related]

  • 15. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
    Hirschowitz BI, Mohnen J, Shaw S.
    Aliment Pharmacol Ther; 1996 Aug 15; 10(4):497-506. PubMed ID: 8853753
    [Abstract] [Full Text] [Related]

  • 16. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.
    Metz DC, Pisegna JR, Ringham GL, Feigenbaum K, Koviack PD, Maton PN, Gardner JD, Jensen RT.
    Dig Dis Sci; 1993 Feb 15; 38(2):245-56. PubMed ID: 8425437
    [Abstract] [Full Text] [Related]

  • 17. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.
    Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT.
    Aliment Pharmacol Ther; 1993 Dec 15; 7(6):597-610. PubMed ID: 8161665
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS, Berardi RR.
    J Am Pharm Assoc (Wash); 2000 Dec 15; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [Abstract] [Full Text] [Related]

  • 19. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
    Bardhan KD, Cherian P, Bishop AE, Polak JM, Romanska H, Perry MJ, Rowland A, Thompson M, Morris P, Schneider A, Fischer R, Ng W, Lühmann R, McCaldin B.
    Am J Gastroenterol; 2001 Jun 15; 96(6):1767-76. PubMed ID: 11419827
    [Abstract] [Full Text] [Related]

  • 20. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
    Metz DC, Sostek MB, Ruszniewski P, Forsmark CE, Monyak J, Pisegna JR.
    Am J Gastroenterol; 2007 Dec 15; 102(12):2648-54. PubMed ID: 17764495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.